Skip to main content
. Author manuscript; available in PMC: 2020 Jun 2.
Published in final edited form as: Transplantation. 2016 Jul;100(7):1415–1424. doi: 10.1097/TP.0000000000000995

TABLE 2.

Trials of C1 INH in transplantation listed in clinicaltrials.gova

Title Phase NCT Number Type Sponsor Status
C1 INH Preoperative and post-kidney transplant to prevent DGF and IRI I 02134314 R, PC, DB Cedars-Sinai Medical Center, Los Angeles, CA Recruiting
Safety and tolerability of Berinert (C1 inhibitor) therapy to prevent AMR in HLA sensitized kidney transplant recipients I 01134510 R, PC, DB Cedars-Sinai Medical Center Completed67
Recombinant human C1 INH for the treatment of early AMR in renal transplantation II 01035593 R, OL Shire, Lexington, MA Withdrawnb
A pilot study to evaluate the use of C1 INH (human) in patients with acute (kidney) AMR II 01147302 R, PC, DB Shire, Lexington, MA Completed68
Combined drug approach to prevent IRI during transplantation of livers I 01886443 SB Universitaire Ziekenhuisen Leuven, Belgium Completed
Combined drug approach to prevent IRI during transplantation of livers (CAPITL) II 02251041 R, SB Universitaire Ziekenhuisen Leuven, Belgium Recruiting
Cinryze as a donor pretreatment strategy in kidney recipients of KDPI>85% organs I 02435732 R, PC, University of Wisconsin Madison, Wl Not yet recruiting
a

No trials are listed in EUdraCT which are not listed here.

b

Sponsor’s comment: “Withdrawn due to Improvements in Clinical Practice (which) Have Reduced The Apparent Incidence of AMR.”

R indicates randomized; PC, placebo controlled; DB, double blinded; SB, single blinded (subject); OL, open label.